Asciminib in HER2+ Breast Cancer Brain Metastases

The purpose of this study is to evaluate the intracranial response rate of a combination of asciminib/trastuzumab for the treatment of patients with metastatic HER2+ breast cancer with brain metastases.

Trial Details

NCT ID
NCT07136428
Phase
PHASE1 / PHASE2
Sponsor
Duke University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Asciminib and Trastuzumab
Locations (sample)
  • Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

  • Age ≥18 years at the time of consent
  • Patients with HER2+ metastatic breast cancer with at least one progressive or new brain metastasis measuring \>5mm; prior local therapy to other in…
  • At least 1 prior standard of care therapy for metastatic disease
  • Must have previously received T-DXd and Tucatinib. If a patient has not received T-DXd or Tucatinib as part of standard early line therapy due to a…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →